Inferra AI / Company / VKTX / Slides
Viking Therapeutics, Inc. — Maintenance+Study+Presentation (company IR deck)
Viking Therapeutics, Inc. (VKTX) · 0 slides · Filed Oct 28, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All VKTX deck slides
Slide 1 — Study: Topline Results
VK2735-102 Maintenance Study: Topline Results September 2026
Slide 2 — Forward-Looking Statements
2 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators’ ability to successfully research, obtain regulatory approvals for, develop and commercialize products based upon our technologies; our ability to obtain and maintain proprietary protection for our technologies and product candidates; our reliance on third parties to manufacture our preclinical and clinical drug supplies; competitive pressures; our ability to obtain and maintain strategic collaborations; compliance with our in- license agreements; our ability to successfully execute on, and receive favorable results from, our proprietary drug development efforts; market acceptance of our drug candidates; retaining members of our senior management; and our ability to raise additional funds to finance our operations. The forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. For more information regarding risks and uncertainties that could affect the results of our operations or financial condition review our filings with the Securities and Exchange Commission (in particular, our most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q).
Slide 3 — Maintenance
3 Expanding on VK2735 Holistic Weight Loss Potential Phase 2 data presented 8/19/2025 • Up to 12.2% body weight reduction after 13 weeks • Encouraging safety and tolerability with 99% of GI-specific Treatment Emergent AEs Mild or Moderate • Extended half-life drives robust patient outcomes Phase 3 obesity and T2D trials expected to begin in 4Q26 VK2735 Oral Today’s Focus Phase 2 data presented 2/27/2024 • Up to 14.7% body weight reduction after 13 weeks • Large and established safety profile and tolerability dataset across multiple trials VANQUISH Phase 3 trials in obesity and T2D fully enrolled with data expected in 2H27 VK2735 SC Maintenance data presented today • Potential to unlock new platform opportunities across maintenance use cases • Establish convenient dosing regimens including monthly or every-other-week while maintaining excellent tolerability Potential of SC to oral maintenance – study expected to begin later this quarter VK2735 SC Maintenance
Slide 4 — VK2735-102: Maintenance Study Design
4 VK2735-102: Maintenance Study Design 38 5-week follow-up 12-week maintenance Weekly SC titration (21 weekly doses) 6-week screening Randomization Part 1: Subcutaneous (SC) maintenance dosing Healthy subjects with BMI ≥30 • Designed to evaluate transition from Weekly (QW) to SC monthly (QM) or every other week (QOW) dosing regimens • Endpoints: Safety, tolerability, PK, weight change 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 22.5 mg monthly SC 20.0 mg monthly SC 17.5 mg monthly SC 15.0 mg monthly SC 10.0 mg monthly SC 10.0 mg QOW SC 7.5 mg QOW SC 5.0 mg QOW SC 17.5 mg weekly SC Placebo weekly SC Placebo weekly SC 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 17.5 mg 20.0 mg 22.5 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 1.25 mg 2.5 mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg 17.5 mg 17.5 mg 17.5 mg 17.5 mg 17.5 mg 17.5 mg 17.5 mg 17.5 mg Placebo 15.0 mg 20.0 mg Maintenance dosing period begins
Slide 5 — Maintenance Study: Induction Weight Loss Through Week 21
5 Maintenance Study: Induction Weight Loss Through Week 21 • Significant and progressive reduction in body weight observed after 21 weeks in all VK2735 cohorts • Up to approximately 19% weight loss from baseline • 17.8% weight loss from baseline for 17.5 mg dose (n=118) • No evidence of plateau Notes: ****p<0.0001. Patients were required to have baseline BMI ≥30 kg/m2. Patients treated with VK2735 were titrated to final doses Body Weight Percent Change from Baseline over 13 Weeks (LSM±SE)
Slide 6 — High Proportion of VK2735 Participants Achieve Key
6 High Proportion of VK2735 Participants Achieve Key Weight Loss Thresholds at Week 21 5% Weight Loss 10% Weight Loss 15% Weight Loss 20% Weight Loss VK2735, Combined n=143 1 98% 90% 65% 32% Placebo n=15 13% 0% 0% 0% p-value vs. placebo <0.0001 <0.0001 <0.0001 <0.01 Notes: 1) Observed values for subjects with weight measurement at W21 visit.
Slide 7 — Maintenance Study: Maintenance of Weight Loss with Every-
7 Maintenance Study: Maintenance of Weight Loss with Every- Other-Week Dosing • Up to approximately 97% maintenance of weight loss observed following transition to every-other-week dosing • Compares favorably to 61% maintenance effect for participants transitioned from 17.5 mg QW to placebo; p<0.01 all cohorts • Weight loss from baseline remains highly significant across all cohorts Percent of Weight Loss Maintained from W21 to W33 (LSM±SE) Notes: Patients were required to have baseline BMI ≥30 kg/m2.
Slide 8 — Maintenance Study: Maintenance of Weight Loss with Monthly
8 Maintenance Study: Maintenance of Weight Loss with Monthly Dosing • Up to approximately 90% maintenance of weight loss observed following transition to monthly dosing • Compares favorably to 61% maintenance effect for participants transitioned from 17.5 mg QW to placebo; p<0.01 all cohorts • Weight loss from baseline remains highly significant across all cohorts Notes: Patients were required to have baseline BMI ≥30 kg/m2. Percent of Weight Loss Maintained from W21 to W33 (LSM±SE)
Slide 9 — Maintenance Study: 17.5 mg Weekly Dosing Provides Highly
9 Maintenance Study: 17.5 mg Weekly Dosing Provides Highly Competitive 22% Weight Loss at W33 • Continued weekly dosing at 17.5 mg leads to progressive weight loss of up to approximately 22% • No plateau observed, suggesting continued weight loss with further dosing • Highly competitive vs. existing multi-agonist therapies dosed for longer periods Body Weight Percent Change from Baseline over 33 Weeks (LSM±SE) Notes: Patients were required to have baseline BMI ≥30 kg/m2. Patients treated with VK2735 were titrated to final doses.
Slide 10 — Discontinuation and GI Tolerability Summary – Induction Phase
10 Discontinuation and GI Tolerability Summary – Induction Phase Through Week 21 Notes: 1) Safety population, includes all randomized subjects who received at least one dose of study drug. 2) Subjects treated with VK2735 were titrated to final dose as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg; Week 15-16 = 20.0 mg; Week 17 = 22.5 mg. Dose Level1,2 Placebo (n=15) VK2735 Combined (n=166) VK2735 15 mg QW (n=15) VK2735 17.5 mg QW (n=121) VK2735 20 mg QW (n=15) VK2735 22.5 mg QW (n=15) Discontinued treatment early 0 (0%) 22 (13%) 2 (13%) 15 (12%) 1 (7%) 4 (27%) Discontinued treatment due to adverse event 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) Treatment emergent adverse events (TEAEs) 7 (47%) 116 (70%) 11 (73%) 83 (69%) 10 (67%) 12 (80%) Common GI AEs, # of Subjects reporting, (%) Nausea Mild 1 (7%) 67 (40%) 6 (40%) 47 (39%) 3 (20%) 11 (73%) Moderate 0 (0%) 3 (2%) 0 (0%) 2 (2%) 0 (0%) 1 (7%) Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Vomiting 1 (7%) 45 (27%) 6 (40%) 32 (26%) 2 (13%) 5 (33%) Diarrhea 3 (20%) 33 (20%) 3 (20%) 24 (20%) 3 (20%) 3 (20%) Constipation 1 (7%) 18 (11%) 1 (7%) 12 (10%) 1 (7%) 4 (27%) Encouraging tolerability despite accelerated titration scheme; GI AEs in-line with expected from GLP-1/GIP agonism
Slide 11 — Discontinuation and GI Tolerability Summary – Every Other Week
11 Discontinuation and GI Tolerability Summary – Every Other Week Maintenance Dosing Through Week 33 Dose Level1,2 Placebo (n=27) VK2735 Combined QOW (n=37) VK2735 5.0 mg QOW (n=12) VK2735 7.5 mg QOW (n=13) VK2735 10.0 mg QOW (n=12) Discontinued treatment early 0 (0%) 1 (3%) 0 (0%) 0 (0%) 1 (8%) Discontinued treatment due to adverse event 0 (0%) 1 (3%) 0 (0%) 0 (0%) 1 (8%) Treatment emergent adverse events (TEAEs) 14 (52%) 14 (38%) 4 (33%) 5 (39%) 5 (42%) Common GI AEs, # of Subjects reporting, (%) Nausea Mild 0 (0%) 2 (5%) 1 (8%) 1 (8%) 0 (0%) Moderate 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Vomiting 2 (7%) 1 (3%) 0 (0%) 0 (0%) 1 (8%) Diarrhea 1 (4%) 2 (5%) 0 (0%) 2 (15%) 0 (0%) Constipation 1 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Rates of common GI AEs similar to placebo following transition from weekly to every-other-week dosing Notes: 1) Safety population, includes all randomized subjects who received at least one dose of study drug on or after Week 21. 2) Subjects treated with VK2735 were titrated to final doses as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg. At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 5.0 mg every other week (QOW); 15 mg weekly to 7.5 mg QOW; 17.5 mg weekly to 10 mg QOW.
Slide 12 — Discontinuation and GI Tolerability Summary – Monthly
12 Discontinuation and GI Tolerability Summary – Monthly Maintenance Dosing Through Week 33 Notes: 1) Safety population, includes all randomized subjects who received at least one dose of study drug on or after Week 21. 2) Subjects treated with VK2735 were titrated to final doses as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg; Week 15-16 = 20.0 mg; Week 17 = 22.5 mg. At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 10.0 mg once monthly (QM); 17.5 mg weekly to 15.0 mg QM; 17.5 mg weekly to 17.5 mg QM; 20.0 mg weekly to 20.0 mg QM; 22.5 mg once weekly to 22.5 mg QM. Dose Level1,2 Placebo (n=27) VK2735 Combined QM (n=66) VK2735 10 mg QM (n=16) VK2735 15 mg QM (n=14) VK2735 17.5 mg QM (n=11) VK2735 20 mg QM (n=14) VK2735 22.5 mg QM (n=11) Discontinued treatment early 0 (0%) 3 (5%) 0 (0%) 1 (7%) 1 (9%) 1 (7%) 0 (0%) Discontinued treatment due to adverse event 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (7%) 0 (0%) Treatment emergent adverse events (TEAEs) 14 (52%) 32 (49%) 7 (44%) 7 (50%) 5 (46%) 7 (50%) 6 (55%) Common GI AEs, # of Subjects reporting, (%) Nausea Mild 0 (0%) 3 (4.5%) 1 (6%) 2 (14%) 0 (0%) 0 (0%) 0 (0%) Moderate 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Vomiting 2 (7%) 5 (8%) 2 (13%) 1 (7%) 1 (9%) 1 (7%) 0 (0%) Diarrhea 1 (4%) 3 (5%) 1 (6%) 0 (0%) 0 (0%) 2 (14%) 0 (0%) Constipation 1 (4%) 2 (3%) 1 (6%) 1 (7%) 0 (0%) 0 (0%) 0 (0%) Rates of common GI AEs similar to placebo following transition from weekly to monthly dosing
Slide 13 — VK2735-102 Study Establishes Maintenance Use Case
13 VK2735-102 Study Establishes Maintenance Use Case • Rapid Induction with Durable, Tolerable Maintenance Potential • Up to ~90% (monthly dosing) and ~97% (every-other-week dosing) of week 21 weight loss maintained at week 33 after switching to less- frequent dosing • Indicates credible maintenance paradigm and reinforces flexibility and platform potential with ability to reach new patient populations • Data supports both substantial weekly weight loss paired with durable, maintenance of that weight loss across multiple less-frequent dosing models • Up to ~19% placebo-adj weight loss at week 21 • ~18% placebo-adj weight loss at week 21 in 17.5mg cohort with up to ~22% placebo-adj weight loss at week 33 on continued 17.5 mg weekly, with no plateau observed • Highly competitive vs. existing therapies dosed for longer periods • Improved AE profile as dosing switches to less-frequent administration indicates potential adherence benefits • Maintenance-phase GI adverse events comparable to placebo; low discontinuation observed • Clean profile suited to primary care prescribing and long-term patient use Rapid Weight Loss Induction Sustained Loss on Maintenance Dosing Tolerability Potentially Amenable for Long Term Use Part 2 of study exploring SC to oral maintenance dosing to begin later this quarter
Slide 14 — Study: Topline Results
VK2735-102 Maintenance Study: Topline Results September 2026